TOP > 外国特許検索 > APOPTOSIS INDUCER

APOPTOSIS INDUCER UPDATE

外国特許コード F110005354
整理番号 S2011-0187-N0
掲載日 2011年9月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP064857
国際公開番号 WO 2011025050
国際出願日 平成22年8月25日(2010.8.25)
国際公開日 平成23年3月3日(2011.3.3)
優先権データ
  • 特願2009-194747 (2009.8.25) JP
発明の名称 (英語) APOPTOSIS INDUCER UPDATE
発明の概要(英語) Disclosed are: an apoptosis inducer which can induce the apoptosis of various types of cells including tumor cells conveniently; and others. The apoptosis inducer is characterized by comprising a peptide (a) or (b) as mentioned below, a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide comprising the amino acid sequence represented by formula (I): C-X-D-X-X-X-X-Y-X-C-X-C; and (b) a peptide which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence represented by the above-mentioned formula (I) and which has an apoptosis-inducing activity.
従来技術、競合技術の概要(英語) BACKGROUND ART
Apoptosis, and one of the forms of cell death, disruption of the nucleus within a cell refers to cell death. Up to now, as the molecular mechanisms of apoptosis in cancer cells death, calcium pathway, death signaling pathway, ceramide pathway, mitochondrial, 5 and p53 of the apoptotic pathway is induced in the path of the two known molecular mechanisms (for example, 'Hashimoto yoshiyuki, new apoptosis molecular medicine, sheep earth Inc., 4 年 2001, pages 10-58' reference). A substance which induces apoptosis are known and many, such as mitomycin and taxol in clinical medicine and the anti-cancer agent is used. These artificial other than, or on a living body such as TNF α FasL (Fas ligand) protein exists in the induction of apoptosis. These artificial, natural apoptosis-inducing substances, such as cancer cells which are harmful to humans can be lethal to cells. As described above, also the anti-cancer agent used in chemotherapy, gene therapy also FasL being advanced studies, and applying this principle. Chemotherapy with, side effects to healthy tissue obstructs a portion of the treatment, effect on the lesion with the expectation that only, a gene therapy using gene transfer into the lesion has been studied. However, actually in the gene-introduced cells will, typically, a portion of the cells and the lesion, the cells were subsequently introduced a gene killed condition, a therapeutically effective protein or the like is not produced more of cells, as a result, the effect of the partial gene therapy in many cases. Therefore, the remaining of the pathological cells, it is required to repeatedly for gene transfer. In addition, the first gene by the introduction of the gene is introduced into the cells which were not, not easily HBlOl and there, the treatment is hindered.
In such a situation, various tumor cells to the cell can be easily induced apoptosis in the development of apoptosis-inducing agents has been desired. The present invention is, in consideration of the above circumstances with an object, shown below, inducer of apoptosis, pharmaceutical composition for the treatment of cancer and the like system according to the invention. (1) (A) or (b) the following peptides, derivatives or salts thereof characterized in that, apoptosis-inducing agents. (a) The following formula (I): (X is any amino acid residues, is a cysteine represents C, D represents an aspartic acid, phenylalanine is F.) A peptide comprising the amino acid sequence. (b) Amino acid sequence represented by the above formula (I) or an amino acid sequence in the 1 deletion, substitution or addition of the amino acid sequence, and, a peptide having apoptosis-inducing activity. In the above- (1) inducing agent, the amino acid sequence shown in formula (I), for example, SEQ ID NO:2 or amino acid sequence shown in SEQ ID NO and 3. In addition, the peptides of (a), for example, shown in SEQ ID NO:5 or SEQ ID NO:7 and comprising an amino acid sequence. (2) In a cell of interest to the above-mentioned (1) cells or cell populations comprising the action of the inducing agent, apoptosis-inducing method. In the method of induction, wherein the step of, for example, the cells of interest or cell population and the step of contacting the inducing agent. (3) The (1) inducing agent, a pharmaceutical composition for the treatment of cancer.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • HIDAI, Chiaki
  • KITANO, Hisataka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close